Health Care • Ophthalmic Goods
$5.05 ▲ +0.15
(+3.06%)
MKT CAP: $210.0M • VOL: 841.6K
52W L $4 52W H $13
RXST // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $134.5M | $139.9M | $89.1M |
| YoY Revenue Growth % | -3.9% | +57.1% | — |
| Gross Profit | $103.0M | $98.9M | — |
| Gross Margin % | 76.6% | 70.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$48.2M | -$36.9M | -$50.1M |
| Operating Margin % | -35.8% | -26.3% | -56.2% |
| Net Income (GAAP) | -$39 | -$27 | -$49 |
| EBITDA (Normalized) | -$45.1M | -$32.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$15.5M | -$16.9M | -$41.6M |
| Capital Expenditures (CapEx) | $3.8M | $5.4M | — |
| Free Cash Flow (FCF) | -$19.3M | -$22.4M | -$41.6M |
| FCF Margin % | -14.4% | -16.0% | -46.7% |
| Return on Invested Capital (ROIC %) | -14.9% | -11.0% | — |
| Cash & Short-Term Equivalents | $19.9M | $16.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $275.7M | $281.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RXST.